

Supplementary Online Content

Sridhar SS, Blais N, Tran B, et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. *JAMA Oncol*. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3927

eTable 1. Reason for Treatment Discontinuation n (%)

eTable 2. \geq Grade 3 Hematologic Toxicities in Both Arms

eFigure 1A. Overall Survival in the nab-Paclitaxel and Paclitaxel Arms

eFigure 1B. Overall Survival Forest Plot

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1: Reason for Treatment Discontinuation n (%)

Reasons Off Protocol Therapy	nab-Paclitaxel (n=96) n (%)	Paclitaxel (n=91) n (%)
Death Due to Disease	2 (2)	1 (1)
Intercurrent Illness	1 (1)	4 (4)
Progressive Disease	50 (52)	50 (50)
Adverse related events	27 (27)	18 (18)
Patient Refusal	5 (5)	7 (7)
Symptomatic Progression	10 (10)	7 (7)
Other	1(1)	4 (4)


eTable 2: ≥ Grade 3 Hematologic Toxicities in Both Arms

Hematologic Toxicities (CTCAE Version 4)	nab-Paclitaxel n (%)	Paclitaxel n (%)
Neutropenia	13 (13)	7 (7)
Anemia	3 (3)	7 (7)
Thrombocytopenia	1 (1)	4 (2)

NCIC CTG TRIAL BL.12

eFigure 1A. Overall Survival in the nab-Paclitaxel and Paclitaxel Arms

Overall Survival



SUMMARY STATISTICS:

Log-Rank test for equality of groups: $p=0.7585$

Stratified Log Rank test: $p=0.7952$

Median for PACLITAXEL: 8.77 -90% C.I. (6.11 ,10.61)

Median for NAB-PACLITAXEL: 7.46 -90% C.I. (6.44 ,8.64)

Survival rate at 0 months for PACLITAXEL: 100% - 90% C.I. (100%, 100%)

Survival rate at 0 months for NAB-PACLITAXEL: 100% - 90% C.I. (100%, 100%)

Stratified Hazard Ratio of NAB-PACLITAXEL/PACLITAXEL: 0.952 - 90 % C.I. (0.695, 1.303)

eFigure 1B. Overall Survival Forest Plot

Treatment Effect on Overall Survival by Factors

Hazard Ratio and 95% CL

